Background: The effective targeted therapy for lung squamous cell carcinoma (SCC) is
needed. The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The …

Purpose Erlotinib had proved efficacy in patients with advanced non-small cell lung cancer,
especially adenocarcinoma. The aim of this study was to evaluate the efficacy of erlotinib in …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …

Background We conducted a phase II trial of erlotinib in patients with advanced non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …